SPA
CRMD icon

Sherbrooke Park Advisers’s CorMedix CRMD Stock Holding History

Sherbrooke Park Advisers’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$148K Sell
12,717
-30,035
-70% -$332K 0.38% 108
2025
Q3 		$497K Buy
42,752
+32,126
+302% +$388K 0.23% 170
2025
Q2 		$131K Buy
+10,626
New +$117K 0.06% 436

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return

Sherbrooke Park Advisers's CRMD Position: Q4 2025 in Review

Sherbrooke Park Advisers reduced its CorMedix (CRMD) stake by 70% in Q4 2025, selling an estimated $332K and leaving 12,717 shares worth $148K. The position accounts for 0.38% of the portfolio, ranked #108.

Sherbrooke Park Advisers first reported a position in CRMD in Q2 2025 and has held it in 3 quarters since. The position peaked at $497K in Q3 2025. 198 funds tracked by Wall St. Rank hold CRMD as of Q4 2025.

  • Sherbrooke Park Advisers held 12,717 shares of CorMedix worth $148K as of Q4 2025.
  • Sherbrooke Park Advisers sold 30,035 CorMedix shares in Q4 2025, an estimated $332K.
  • CorMedix made up 0.38% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #108 holding.
  • Sherbrooke Park Advisers first reported a position in CorMedix in Q2 2025 and has held it in 3 quarters since.
  • Sherbrooke Park Advisers's CorMedix position peaked at $497K in Q3 2025.
  • 198 funds tracked by Wall St. Rank held CorMedix as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.